Table 2.

Proposed criteria to be considered for stratifying risk of infectivity of symptomatic immunocompromised patients with COVID-19. These criteria should not be considered guidelines and should be subject to modification with the emergence of new data and based on hospital bed capacity

Degree of immunocompromise	Infection prevention approach
Moderatea	Discontinue precautions 24 h after resolution of fever (without antipyretics), improvement of symptoms, and at least 20 days since first positive test
Severeb	Consider test-based strategy using PCRs under infectious disease specialist guidance Discontinue precautions with upon negative PCR resultc

^aImmunocompromised, moderate: immunocompromising conditions not classified as severe, including (but not limited to) chemotherapy for cancer, untreated HIV infection with CD4 T lymphocyte count < 200, combined primary immunodeficiency disorder, and receipt of prednisone > 20 mg/day for more than 14 days

^bImmunocompromised, severe: hematologic malignancy on treatment; hematopoietic cell transplant or CAR-T-cell therapy within the preceding 6 months, or with systemic therapy for acute GVHD in the past 6 months; solid organ transplant (SOT) within the preceding 6 months; SOT or heme malignancy receiving treatment with specific immunocompromising therapies (thymoglobulin, alemtuzumab, fludarabine, cladribine, or anti-CD20 monoclonal antibodies) in the preceding 6 months; other serious T- and/or B-cell deficiencies determined on a case-by-case basis that may include untreated HIV with CD4 T lymphocyte count < 100, rituximab therapy, and select primary immunodeficiency disorders

^cSome centers may favor 2 negative PCR results given reports of intermittent shedding of infectious virus